Core Viewpoint - Addex Therapeutics will announce its Full-Year 2024 Financial Results on April 25, 2025, and provide a business update along with a review of its product pipeline during a teleconference and webcast [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4]. - The company has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [4]. - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs targeting schizophrenia, mood disorders, and mild neurocognitive disorders [4]. - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [4].
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025